In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $1.22 in the last session, down -1.61% from day before closing price of $1.24. In other words, the price has decreased by -$1.61 from its previous closing price. On the day, 1.07 million shares were traded. ACRS stock price reached its highest trading level at $1.295 during the session, while it also had its lowest trading level at $1.215.
Ratios:
We take a closer look at ACRS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 05 ’24 when Leonard Braden Michael bought 206,025 shares for $1.24 per share. The transaction valued at 256,357 led to the insider holds 14,250,000 shares of the business.
Leonard Braden Michael bought 167,544 shares of ACRS for $216,400 on Aug 02 ’24. The 10% Owner now owns 14,043,975 shares after completing the transaction at $1.29 per share. On Jul 31 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 100,000 shares for $1.33 each. As a result, the insider paid 132,640 and bolstered with 13,876,421 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 86943056 and an Enterprise Value of -37748960. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.79 while its Price-to-Book (P/B) ratio in mrq is 0.61. Its current Enterprise Value per Revenue stands at -1.213.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $9.95, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 1.59%, while the 200-Day Moving Average is calculated to be -18.91%.
Shares Statistics:
According to the various share statistics, ACRS traded on average about 875.01K shares per day over the past 3-months and 611480 shares per day over the past 10 days. A total of 70.89M shares are outstanding, with a floating share count of 65.48M. Insiders hold about 8.12% of the company’s shares, while institutions hold 76.22% stake in the company. Shares short for ACRS as of 1721001600 were 2158607 with a Short Ratio of 2.47, compared to 1718323200 on 4457886. Therefore, it implies a Short% of Shares Outstanding of 2158607 and a Short% of Float of 3.61.
Earnings Estimates
The dynamic stock of Aclaris Therapeutics Inc (ACRS) is currently attracting attention from 9.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.1 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.53 and -$1.21 for the fiscal current year, implying an average EPS of -$0.8. EPS for the following year is -$0.62, with 9.0 analysts recommending between -$0.4 and -$1.35.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $1.82M. It ranges from a high estimate of $2.5M to a low estimate of $660k. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $1.9MFor the next quarter, 9 analysts are estimating revenue of $1.95M. There is a high estimate of $2.75M for the next quarter, whereas the lowest estimate is $660k.
A total of 8 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $10.19M, while the lowest revenue estimate was $4.37M, resulting in an average revenue estimate of $8.14M. In the same quarter a year ago, actual revenue was $31.25MBased on 8 analysts’ estimates, the company’s revenue will be $8.24M in the next fiscal year. The high estimate is $13.2M and the low estimate is $2.63M.
